Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints  Michael Camilleri, Allen W. Mangel, Sheri E. Fehnel, Douglas A. Drossman, Emeran A. Mayer, Nicholas J. Talley  Clinical Gastroenterology and Hepatology  Volume 5, Issue 5, Pages 534-540 (May 2007) DOI: 10.1016/j.cgh.2007.03.004 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Baseline pain severity does not affect adequate relief responses in IBS patients. Patients were enrolled in a phase II IBS trial evaluating dextofisopam versus placebo. Percent of weeks that patients reported adequate relief is shown. Stratification of patients by baseline pain severity scores revealed no impact of baseline scores on adequate relief responses for either dextofisopam or placebo-treated patients (data provided by Dr Steve Leventer, Vela/Pharmos Pharmaceutics). Clinical Gastroenterology and Hepatology 2007 5, 534-540DOI: (10.1016/j.cgh.2007.03.004) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Reproducibility of IBS-SS. Note the relatively poor reproducibility in the moderate range of severity. From Francis et al.25 Clinical Gastroenterology and Hepatology 2007 5, 534-540DOI: (10.1016/j.cgh.2007.03.004) Copyright © 2007 AGA Institute Terms and Conditions